Abstract

Background. Spinal muscular atrophy (SMA) is an inherited disease with progressive muscle weakness and atrophy. Despite the new treatments developed recently, primary and secondary effects of muscle weakness in patients with SMA cause mortality and morbidity. The aim of this study is to identify common problems in the follow-up of patients after new treatment modalities and to examine the difficulties in management of these problems.

Methods. The study included 16 patients diagnosed with SMA type 1 according to clinical findings and genetic results between 2017 and 2022. The patients were divided into two groups as living and deceased, and complications were examined and compared between the groups.

Results. The patients comprised 8 (50%) females and 8 (50%) males with a median age at diagnosis of 3 months. The patients had a history of gastrointestinal problems, orthopedic problems, infection and sepsis, and especially respiratory distress. Death occurred in 8 (50%) patients during follow-up (median age 38 months). Mortality was higher in patients who needed tracheostomy and had gastroesophageal reflux. The survival rate was better in patients who received more nusinersen treatment and had a higher CHOP-INTEND score.

Conclusions. Despite new-generation treatments for SMA type 1, morbidity and mortality rates remain very high. As the survival rate in SMA type 1 increases, the incidence of complications similar to those frequently seen in SMA type 2 and type 3 patients also increases. The follow-up and treatment of patients with SMA should be undertaken by a multidisciplinary team.

Keywords: Spinal muscular atrophy type 1, mortality, morbidity, nusinersen, SMN1

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Güzin Y, Büyükşen O, Gençpınar P, Olgaç Dündar N, Baydan F. Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment. Turk J Pediatr 2024; 66: 567-577. https://doi.org/10.24953/turkjpediatr.2024.4527

References

  1. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33: 831-846. https://doi.org/10.1016/j.ncl.2015.07.004
  2. Mostacciuolo ML, Danieli GA, Trevisan C, Müller E, Angelini C. Epidemiology of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology 1992; 11: 34-38. https://doi.org/10.1159/000110905
  3. Thieme A, Mitulla B, Schulze F, Spiegler AW. Epidemiological data on Werdnig-Hoffmann disease in Germany (West-Thüringen). Hum Genet 1993; 91: 295-297. https://doi.org/10.1007/BF00218278
  4. Darras BT. Spinal muscular atrophies. Pediatr Clin North Am 2015; 62: 743-766. https://doi.org/10.1016/j.pcl.2015.03.010
  5. Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83: 810-817. https://doi.org/10.1212/WNL.0000000000000741
  6. Iannaccone ST. Modern management of spinal muscular atrophy. J Child Neurol 2007; 22: 974-978. https://doi.org/10.1177/0883073807305670
  7. Wang HY, Ju YH, Chen SM, Lo SK, Jong YJ. Joint range of motion limitations in children and young adults with spinal muscular atrophy. Arch Phys Med Rehabil 2004; 85: 1689-1693. https://doi.org/10.1016/j.apmr.2004.01.043
  8. Ludolph AC, Wurster CD. Therapeutic advances in SMA. Curr Opin Neurol 2019; 32: 777-781. https://doi.org/10.1097/WCO.0000000000000738
  9. Angilletta I, Ferrante R, Giansante R, et al. Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies. Int J Mol Sci 2023; 24: 14873. https://doi.org/10.3390/ijms241914873
  10. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015; 51: 157-167. https://doi.org/10.1002/mus.24497
  11. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007; 22: 1027-1049. https://doi.org/10.1177/0883073807305788
  12. Hoy SM. Nusinersen: first global approval. Drugs 2017; 77: 473-479. https://doi.org/10.1007/s40265-017-0711-7
  13. Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs 2021; 35: 1317-1328. https://doi.org/10.1007/s40263-021-00878-x
  14. Veldhoen ES, Wijngaarde CA, Hulzebos EHJ, et al. Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet J Rare Dis 2022; 17: 70. https://doi.org/10.1186/s13023-022-02227-7
  15. Lagae L, Proesmans M, Van den Hauwe M, Vermeulen F, De Waele L, Boon M. Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies. Front Pediatr 2024; 12: 1366943. https://doi.org/10.3389/fped.2024.1366943
  16. Berglund A, Berkö S, Lampa E, Sejersen T. Survival in patients diagnosed with SMA at less than 24 months of age in a population-based setting before, during and after introduction of nusinersen therapy. Experience from Sweden. Eur J Paediatr Neurol 2022; 40: 57-60. https://doi.org/10.1016/j.ejpn.2022.07.005
  17. Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017; 81: 355-368. https://doi.org/10.1002/ana.24864
  18. Cherchi C, Chiarini Testa MB, Deriu D, et al. All you need is evidence: what we know about pneumonia in children with neuromuscular diseases. Front Pediatr 2021; 9: 625751. https://doi.org/10.3389/fped.2021.625751
  19. Araki S, Hayashi M, Tamagawa K, et al. Neuropathological analysis in spinal muscular atrophy type II. Acta Neuropathol 2003; 106: 441-448. https://doi.org/10.1007/s00401-003-0743-9
  20. Simonds AK. Chronic hypoventilation and its management. Eur Respir Rev 2013; 22: 325-332. https://doi.org/10.1183/09059180.00003113
  21. Hepkaya E, Kılınç Sakallı AA, Ülkersoy İ, et al. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy. Pediatr Int 2022; 64: e15310. https://doi.org/10.1111/ped.15310
  22. Chen KA, Widger J, Teng A, Fitzgerald DA, D’Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience. Paediatr Respir Rev 2021; 39: 54-60. https://doi.org/10.1016/j.prrv.2020.09.002
  23. Gonski K, Chuang S, Teng A, et al. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience. Neuromuscul Disord 2023; 33: 531-538. https://doi.org/10.1016/j.nmd.2023.04.007
  24. Nickol AH, Hart N, Hopkinson NS, Moxham J, Simonds A, Polkey MI. Mechanisms of improvement of respiratory failure in patients with restrictive thoracic disease treated with non-invasive ventilation. Thorax 2005; 60: 754-760. https://doi.org/10.1136/thx.2004.039388
  25. Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007; 69: 1931-1936. https://doi.org/10.1212/01.wnl.0000290830.40544.b9
  26. Gilgoff IS, Kahlstrom E, MacLaughlin E, Keens TG. Long-term ventilatory support in spinal muscular atrophy. J Pediatr 1989; 115: 904-909. https://doi.org/10.1016/s0022-3476(89)80740-1
  27. Bach JR. The use of mechanical ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion for. Paediatr Respir Rev 2008; 9: 45-56. https://doi.org/10.1016/j.prrv.2007.11.003
  28. Lavie M, Diamant N, Cahal M, et al. Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience. Pediatr Pulmonol 2021; 56: 291-298. https://doi.org/10.1002/ppul.25140
  29. Ionasescu V, Christensen J, Hart M. Intestinal pseudo-obstruction in adult spinal muscular atrophy. Muscle Nerve 1994; 17: 946-948. https://doi.org/10.1002/mus.880170816
  30. de-Andrés-Beltrán B, Güeita-Rodríguez J, Palacios-Ceña D, Rodríguez-Fernández ÁL. Clinical and functional characteristics of a new phenotype of SMA type I among a national sample of Spanish children: a cross-sectional study. Children (Basel) 2023; 10: 892. https://doi.org/10.3390/children10050892
  31. Dipasquale V, Morello R, Romano C. Gastrointestinal and nutritional care in pediatric neuromuscular disorders. World J Clin Pediatr 2023; 12: 197-204. https://doi.org/10.5409/wjcp.v12.i4.197
  32. Moore GE, Lindenmayer AW, McConchie GA, Ryan MM, Davidson ZE. Describing nutrition in spinal muscular atrophy: a systematic review. Neuromuscul Disord 2016; 26: 395-404. https://doi.org/10.1016/j.nmd.2016.05.005
  33. Chacko A, Marshall J, Taylor O, McEniery J, Sly PD, Gauld LM. Dysphagia and lung disease in children with spinal muscular atrophy treated with disease-modifying agents. Neurology 2023; 100: 914-920. https://doi.org/10.1212/WNL.0000000000206826
  34. Birnkrant DJ, Pope JF, Martin JE, Repucci AH, Eiben RM. Treatment of type I spinal muscular atrophy with noninvasive ventilation and gastrostomy feeding. Pediatr Neurol 1998; 18: 407-410. https://doi.org/10.1016/s0887-8994(97)00227-0
  35. Lavie M, Rochman M, Sagi L, et al. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients. Pediatr Pulmonol 2022; 57: 686-694. https://doi.org/10.1002/ppul.25795
  36. Poruk KE, Davis RH, Smart AL, et al. Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I. Neuromuscul Disord 2012; 22: 966-973. https://doi.org/10.1016/j.nmd.2012.04.008
  37. Li YJ, Chen TH, Wu YZ, Tseng YH. Metabolic and nutritional issues associated with spinal muscular atrophy. Nutrients 2020; 12: 3842. https://doi.org/10.3390/nu12123842
  38. Yerushalmy-Feler A, Levy D, Sagi L, et al. Nutritional therapy in children with spinal muscular atrophy in the era of nusinersen. J Pediatr Gastroenterol Nutr 2021; 72: e154-e160. https://doi.org/10.1097/MPG.0000000000003055
  39. Tilton AH, Miller MD, Khoshoo V. Nutrition and swallowing in pediatric neuromuscular patients. Semin Pediatr Neurol 1998; 5: 106-115. https://doi.org/10.1016/s1071-9091(98)80026-0
  40. Darras BT, Guye S, Hoffart J, et al. Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: an observational retrospective study in the United States. Muscle Nerve 2022; 66: 84-90. https://doi.org/10.1002/mus.27556
  41. Kinali M, Banks LM, Mercuri E, Manzur AY, Muntoni F. Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics 2004; 35: 325-328. https://doi.org/10.1055/s-2004-830366
  42. Tangsrud SE, Carlsen KC, Lund-Petersen I, Carlsen KH. Lung function measurements in young children with spinal muscle atrophy; a cross sectional survey on the effect of position and bracing. Arch Dis Child 2001; 84: 521-524. https://doi.org/10.1136/adc.84.6.521
  43. Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. Neurology 2010; 74: 833-838. https://doi.org/10.1212/WNL.0b013e3181d3e308
  44. Haaker G, Fujak A. Proximal spinal muscular atrophy: current orthopedic perspective. Appl Clin Genet 2013; 6: 113-120. https://doi.org/10.2147/TACG.S53615
  45. Al Amrani F, Amin R, Chiang J, et al. Scoliosis in spinal muscular atrophy type 1 in the nusinersen era. Neurol Clin Pract 2022; 12: 279-287. https://doi.org/10.1212/CPJ.0000000000001179
  46. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999; 3: 49-51.
  47. Salazar R, Montes J, Dunaway Young S, et al. Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: implications for motor function. Pediatr Phys Ther 2018; 30: 209-215. https://doi.org/10.1097/PEP.0000000000000515
  48. Bieniaszewska A, Sobieska M, Gajewska E. Prospective analysis of functional and structural changes in patients with spinal muscular atrophy-a pilot study. Biomedicines 2022; 10: 3187. https://doi.org/10.3390/biomedicines10123187
  49. Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 1994; 4: 497-502. https://doi.org/10.1016/0960-8966(94)90090-6
  50. Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017; 82: 883-891. https://doi.org/10.1002/ana.25101
  51. Krupa D, Czech M, Chudzyńska E, Koń B, Kostera-Pruszczyk A. Real world evidence on the effectiveness of nusinersen within the national program to treat spinal muscular atrophy in Poland. Healthcare (Basel) 2023; 11: 1515. https://doi.org/10.3390/healthcare11101515
  52. Valencia B, Bach JR. Eighteen years with spinal muscular atrophy (SMA) type 1. Tanaffos 2013; 12: 70-73.
  53. Bach JR. Medical considerations of long-term survival of Werdnig-Hoffmann disease. Am J Phys Med Rehabil 2007; 86: 349-355. https://doi.org/10.1097/PHM.0b013e31804b1d66
  54. Kawashima H, Ishii C, Yamanaka G, et al. Myopathy and neurogenic muscular atrophy in unexpected cardiopulmonary arrest. Pediatr Int 2011; 53: 159-161. https://doi.org/10.1111/j.1442-200X.2010.03211.x
  55. Belančić A, Strbad T, Kučan Štiglić M, Vitezić D. Effectiveness of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Croatian real-world data. J Clin Med 2023; 12: 2839. https://doi.org/10.3390/jcm12082839
  56. Destro F, Marinoni F, Russo T, Selvaggio G, Riccipetitoni G. Spinal muscular atrophy (SMA) from the urological point of view: assessment of the urinary function in 38 patients. 2020; 7: 1789397. https://doi.org/10.1080/2331205X.2020.1789397
  57. Gatti JM, Perez-Brayfield M, Kirsch AJ, Smith EA, Massad HC, Broecker BH. Acute urinary retention in children. J Urol 2001; 165: 918-921.
  58. Gök A, Saygılı SK, Kuruğoğlu S, Saltık S, Canpolat N. Children with type 1 spinal muscular atrophy are at increased risk for nephrolithiasis. Pediatr Neurol 2024; 150: 32-36. https://doi.org/10.1016/j.pediatrneurol.2023.10.006
  59. Hachiya Y, Arai H, Hayashi M, et al. Autonomic dysfunction in cases of spinal muscular atrophy type 1 with long survival. Brain Dev 2005; 27: 574-578. https://doi.org/10.1016/j.braindev.2005.02.009
  60. Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat 2014; 224: 15-28. https://doi.org/10.1111/joa.12083
  61. Poets C, Heyer R, von der Hardt H, Walter GF. Acute respiratory insufficiency as the initial clinical manifestation of spinal muscular atrophy. Monatsschr Kinderheilkd 1990; 138: 157-159.
  62. de Queiroz Campos Araujo AP, de Queiroz Campos Araujo IP, de Queiroz Campos Araujo A. Autonomic nervous system dysfunction in motor neuron diseases. J Rare Dis Res Treat. 2018;3:1–5. https://doi.org/10.29245/2572-9411/2018/1.1136
  63. Darbà J. Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis. Orphanet J Rare Dis 2020; 15: 8. https://doi.org/10.1186/s13023-019-1287-y